세계의 육종 치료제 시장 규모 조사 및 예측 : 치료 유형별(화학요법, 표적요법), 지역별 분석(2022-2029년)

Global Sarcoma Drugs Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Sarcoma is a type of cancer that can appear anywhere on the body. Sarcomas, also referred to as soft tissue sarcomas, are a broad category of tumors that develop in the bones and soft tissues. Soft tissue sarcomas form in the tissues that connect, envelop, and support other body structures. The muscle, fat, blood vessels, nerves, tendons, and joint lining make up this framework. There are more than 70 different types of sarcoma. The way that the sarcoma is treated will depend on the type, location, and other factors. Malignant bone tumours and soft tissue sarcoma are two conditions for which sarcoma drugs can be used. Soft tissue sarcomas include rhabdomyosarcoma, synovial cell sarcoma, leiomyosarcoma, and dermatofibrosarcoma. Chemotherapy, targeted medication therapy, and other procedures are part of the sarcoma treatment. The key factor driving the market growth is rise in the prevalence of soft tissue sarcoma, increasing number of product approval for new sarcoma drugs, and growing adoption of key strategies such as acquisition, collaboration, agreement and partnership by key market players that anticipated to support the market growth during forecast period.

Moreover, the rising prevalence of soft tissue sarcoma is anticipated to create the lucrative demand for the sarcoma drugs market. For instance, The American Cancer Society estimates that 12,750 new cases of soft tissue sarcoma will be identified across the country, 7,240 of which will be male and 5,510 of which will be female. According to this society's estimates of mortality, 5,270 Americans are predicted to die by sarcoma in 2019. It has been reported that about 40 people in 1 million have Sarcoma in the United States yearly. Additionally, rising investment for the research and development of sarcoma drugs is anticipated to create the lucrative opportunity for the market during forecast period. However, the high cost of Sarcoma Drugs stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Sarcoma Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, rising the number of research activities, growing technological advancement in the healthcare sector and increasing the prevalence of soft tissue sarcoma in the region. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as increase in expenditure by government organization to develop healthcare sector, rise in prevalence of cancer and growing the number of sarcoma drugs industry would create lucrative growth prospects for the Sarcoma Drugs market across Asia Pacific region.

Major market players included in this report are:

• Baxter Healthcare Corporation
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company Limited
• AgonOX, Inc.
• Eisai Co., Ltd.
• GlaxoSmithKline, plc.
• Hoffmann-La Roche AG.
• Johnson and Johnson
• MERCK & CO., Inc
• Novartis AG

Recent Developments in the Market:

• In 2020, Junshi Biosciences, a worldwide biopharmaceutical company, acquired FDA approval for Orphan Drug name for toripalimab to treat soft tissue sarcoma. This approval is anticipated to help the company offer innovative products and bring in new clients, boosting revenue.

Global Sarcoma Drugs Market Report Scope:

• Historical Data: 2019-2020-2021
• Base Year for Estimation: 2021
• Forecast period: 2022-2029
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Treatment Type, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Treatment Type:

• Chemotherapy
• Targeted Therapy

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Sarcoma Drugs Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Sarcoma Drugs Market, by Treatment Type, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Sarcoma Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Sarcoma Drugs Market Dynamics

• 3.1. Sarcoma Drugs Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rise in the prevalence of soft tissue sarcoma
    • 3.1.1.2. Increasing number of product approval for new sarcoma drugs
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Sarcoma Drugs
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising investment for the research and development of sarcoma drugs

Chapter 4. Global Sarcoma Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Sarcoma Drugs Market, by Treatment Type

• 6.1. Market Snapshot
• 6.2. Global Sarcoma Drugs Market by Treatment Type, Performance - Potential Analysis
• 6.3. Global Sarcoma Drugs Market Estimates & Forecasts by Treatment Type 2019-2029 (USD Billion)
• 6.4. Sarcoma Drugs Market, Sub Segment Analysis
  • 6.4.1. Chemotherapy
  • 6.4.2. Targeted Therapy

Chapter 7. Global Sarcoma Drugs Market, Regional Analysis

• 7.1. Sarcoma Drugs Market, Regional Market Snapshot
• 7.2. North America Sarcoma Drugs Market
  • 7.2.1. U.S. Sarcoma Drugs Market
    • 7.2.1.1. Treatment Type breakdown estimates & forecasts, 2019-2029
  • 7.2.2. Canada Sarcoma Drugs Market
• 7.3. Europe Sarcoma Drugs Market Snapshot
  • 7.3.1. U.K. Sarcoma Drugs Market
  • 7.3.2. Germany Sarcoma Drugs Market
  • 7.3.3. France Sarcoma Drugs Market
  • 7.3.4. Spain Sarcoma Drugs Market
  • 7.3.5. Italy Sarcoma Drugs Market
  • 7.3.6. Rest of Europe Sarcoma Drugs Market
• 7.4. Asia-Pacific Sarcoma Drugs Market Snapshot
  • 7.4.1. China Sarcoma Drugs Market
  • 7.4.2. India Sarcoma Drugs Market
  • 7.4.3. Japan Sarcoma Drugs Market
  • 7.4.4. Australia Sarcoma Drugs Market
  • 7.4.5. South Korea Sarcoma Drugs Market
  • 7.4.6. Rest of Asia Pacific Sarcoma Drugs Market
• 7.5. Latin America Sarcoma Drugs Market Snapshot
  • 7.5.1. Brazil Sarcoma Drugs Market
  • 7.5.2. Mexico Sarcoma Drugs Market
  • 7.5.3. Rest of Latin America Sarcoma Drugs Market
• 7.6. Rest of The World Sarcoma Drugs Market

Chapter 8. Competitive Intelligence

• 8.1. Top Market Strategies
• 8.2. Company Profiles
  • 8.2.1. Baxter Healthcare Corporation
    • 8.2.1.1. Key Information
    • 8.2.1.2. Overview
    • 8.2.1.3. Financial (Subject to Data Availability)
    • 8.2.1.4. Product Summary
    • 8.2.1.5. Recent Developments
  • 8.2.2. Bristol-Myers Squibb Company
  • 8.2.3. Daiichi Sankyo Company Limited
  • 8.2.4. AgonOX, Inc.
  • 8.2.5. Eisai Co., Ltd.
  • 8.2.6. GlaxoSmithKline, plc.
  • 8.2.7. Hoffmann-La Roche AG.
  • 8.2.8. Johnson and Johnson
  • 8.2.9. MERCK & CO., Inc
  • 8.2.10. Novartis AG

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption